araag2/HINT huggingface dataset:
Clinical trial NCT00634933 (phase 2, status: terminated)
Conditions: arthritis, rheumatoid
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: tru-015, methylprednisolone, prednisone, tru-015, methylprednisolone, prednisone, tru-015, methylprednisolone, prednisone
SMILES: [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C
Reason stopped: 
    the study was terminated on 21 june 2010 due to results not meeting the primary endpoint. no
    safety reasons contributed to the termination of the study.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of active seropositive rheumatoid arthritis on a stable dose of
             methotrexate (7.5-25 mg weekly) for at least 12 weeks with or without a history of
             anti-TNF use.

        Exclusion Criteria:

          -  Any prior use of rituximab or other B cell depleting agents.

          -  Any significant health problem other than rheumatoid arthritis

          -  Clinically significant laboratory abnormalities
Clinical trial NCT00475904 (phase 2, status: completed)
Conditions: post herpetic neuralgia, phn, neuropathy, nerve pain
ICD codes: G50.0, M54.81, B02.22, M79.2, G58.0, G61.1, A52.15, G60.3, G61.82, H46.2, H46.3
Drugs: epicept-np-1 cream, gabapentin capsules, placebo
SMILES: NCC1(CC(O)=O)CCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients with pain for ≥ 3 months following onset of a herpes zoster rash

        Exclusion Criteria:

          -  Clinically significant intercurrent illness (e.g., endocrine, cardiac, hepatic, renal,
             neurologic, hematologic, skeletal) that the investigator determines could interfere
             with the efficacy or safety assessments.
Clinical trial NCT00698841 (phase 2, status: completed)
Conditions: advanced cancer
ICD codes: K74.02, G47.22, H35.3133, H35.3134, H35.3113, H35.3114, H35.3123
Drugs: cetuximab
SMILES: [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
Eligibility criteria:

        Inclusion criteria:

          -  Advanced or metastatic malignant disease originating from solid tumors

          -  Adequate recovery from previous therapy or intervention; at least 21 days since major
             surgery or prior radiation therapy

          -  Measurable or evaluable disease

        Exclusion criteria:

          -  Women of childbearing potential (WOCBP) who are breastfeeding, pregnant, or unwilling
             or unable to use acceptable contraception during the study and for at least 12 weeks
             after the last on-study dose of cetuximab

          -  Men unwilling to use acceptable contraception during the study if engaged in sexual
             relations with a WOCBP

          -  Symptomatic brain metastasis

          -  History of myocardial infarction 6 months or less prior to study entry, of severe
             congestive heart failure, of uncontrolled angina, or of uncontrolled arrhythmias

          -  Clinically relevant abnormality on screening electrocardiogram (ECG), preventing an
             accurate measurement of the QT interval

          -  Congenital long QT syndrome

          -  History of risk factors for ventricular tachycardia or Torsades de pointes or history
             of fainting, unexplained loss of consciousness, or convulsions

          -  Prolonged QTc interval on screening ECG (greater than 470 msec) using Fridericia's
             correction formula

          -  Heart rate slower than 50 bpm or faster than 100 bpm at rest during screening ECG
             measurements

          -  Implantable pacemaker or automatic implantable cardioverter defibrillator

          -  Sustained supine systolic blood pressure higher than 150 mmHg or lower than 90 mmHg or
             a diastolic blood pressure lower than 45 mmHg or higher than 95 mmHg at screening

          -  Known history of arterial thrombotic events within 6 months prior to study initiation

          -  Known history of significant peripheral artery disease

          -  Current participation in a clinical trial with another investigational new drug or
             device

          -  Receipt of an investigational new drug or device within 21 days prior to enrollment in
             this study
Clinical trial NCT00031590 (phase 2, status: terminated)
Conditions: brain tumors, central nervous system tumors, medulloblastoma
ICD codes: C71.7, C71.9, C79.31, D33.0, D33.1, D33.2, D49.6, C72.9, D33.9, D43.9, D33.7, D43.8
Drugs: cisplatin, cyclophosphamide, etoposide, lomustine, vincristine
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, ClCCN(CCCl)P1(=O)NCCCO1, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, ClCCN(N=O)C(=O)NC1CCCCC1, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
Reason stopped: 
    the study was terminated prematurely due to slow accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          1. Histologically confirmed medulloblastoma

          2. Standard-risk disease

          3. No residual tumor greater than 1.5 cm^2 after resection by postoperative MRI

               -  No tumor in the spinal or cerebral subarachnoid space by MRI

               -  No tumor in the subarachnoid space by Cerebrospinal fluid (CSF)

               -  No failure to perform staging studies (spine MRI and CSF cytology) preoperatively
                  or postoperatively

          4. Must begin radiotherapy on study within 28 days after surgery

        Exclusion Criteria:

          1. Prior radiotherapy and anti-tumor chemotherapy other than corticosteroids are not
             allowed.

          2. Pregnant females will not be eligible

          3. Patients must begin radiotherapy on protocol within 28 days of completion of surgery.
             Exceptions need to be approved by the Principal Investigator.

          4. Patients with the following will not be eligible:

               -  > 1.5cm3 residual tumor following resection as indicated by post-operative MRI.

               -  tumor in spinal or cerebral subarachnoid space either by MRI of brain and spine

               -  tumor in subarachnoid space by CSF cytology

               -  failure to perform staging studies (spine MRI, CSF cytology) either pre- or post-
                  operatively
Clinical trial NCT00002735 (phase 2, status: terminated)
Conditions: head and neck cancer
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: induction chemotherapy, cisplatin, fluorouracil
SMILES: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    terminated due to poor accrual.
  
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically confirmed squamous cell carcinoma of the
        hypopharynx or base of the tongue that is newly diagnosed and considered resectable For
        hypopharyngeal cancer, total laryngectomy would be required surgery Disease staged by
        clinical exam, endoscopy, and CT or MRI Stage III that is T2-3 N0-1 M0 Stage IV that is
        T2-3 N2-3 M0 Measurable or evaluable disease other than pleural effusion, ascites, or
        disease documented by indirect evidence Closed to patients with cancer of the base of
        tongue as of 11/15/1998

        PATIENT CHARACTERISTICS: Age: Adult Performance status: SWOG 0 or 1 Hematopoietic: WBC at
        least 3,000/mm3 Absolute neutrophil count at least 1,500/mm3 Platelet count at least
        100,000/mm3 Hepatic: Bilirubin no greater than 2 times normal AST or ALT no greater than 3
        times normal Renal: Creatinine no greater than 2 times normal Creatinine clearance at least
        60 mL/min Magnesium normal (supplementation allowed) Other: Average hearing loss in both
        ears no greater than 40 dB in 50-2,000 Hz range No second malignancy within 5 years except:
        Adequately treated nonmelanomatous skin cancer Carcinoma in situ of the cervix Stage I/II
        cancer (other than head/neck) in complete remission Not pregnant or nursing Effective
        contraception required of fertile patients

        PRIOR CONCURRENT THERAPY: No prior therapy
Clinical trial NCT01037127 (phase 2, status: completed)
Conditions: cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: gsk1120212
SMILES: CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Metastatic cutaneous melanoma that was previously treated with: (Cohort A) a BRAF
             inhibitor either with or without other prior therapy. (Cohort B) at least 1 prior
             chemotherapy or immunotherapy, without treatment with a BRAF inhibitor.

          -  Documented positive BRAF mutation (V600E, V600K, or V600D).

          -  Subjects must provide archived tumor tissue or undergo fresh tumor biopsy prior to
             enrollment.

          -  The subject must have a radiographically measurable tumor.

          -  The subject is able to carry out daily life activities without significant difficulty
             (ECOG performance status score of 0 or 1).

          -  Able to swallow and retain oral medication.

          -  Sexually active subjects must use acceptable methods of contraception during the
             course of the study.

          -  Adequate organ system function and blood cell counts.

        Exclusion Criteria:

          -  The subject has had major surgery or received certain types of cancer therapy within
             21 days before starting the study.

          -  Previous treatment with a MEK inhibitor.

          -  Current use of a prohibited medication listed in the protocol.

          -  Uncontrolled glaucoma.

          -  Brain metastasis, unless previously treated with surgery or stereotactic radiosurgery,
             and the disease has been stable for at least 2 months prior to enrollment.

          -  Current severe or uncontrolled systemic disease.

          -  History of clinically significant heart, lung, or eye/vision problems.

          -  Significant unresolved side effects from previous anti-cancer therapy.

          -  The subject is pregnant or breastfeeding.
Clinical trial NCT00634036 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: pioglitazone, placebo
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Asthma diagnosed by a physician at least 1 year prior to study enrollment

          -  Poorly-controlled asthma at study enrollment

          -  Non smokers (stopped smoking at least 1 year ago) and limited life-time history of
             smoking

          -  Body mass index 30-60

          -  Responds to methacholine challenge test with PC20 of <16 mg/ml

          -  On a stable dose of inhaled corticosteroid for at least 4 weeks prior to study entry

          -  FEV1 >60% predicted

          -  Able to obtain weekly weights at home

        Exclusion Criteria:

          -  Systemic steroids within the past 4 weeks

          -  Lung pathology other than asthma

          -  Other significant non-pulmonary co-morbidities such as: coronary artery disease,
             peripheral vascular disease, cerebrovascular disease, congestive heart failure with an
             ejection fraction <50%, liver disease or elevated liver enzymes at baseline,
             malignancy (excluding non-melanoma skin cancers), AIDS, renal failure with serum
             creatinine >3.0, or disorders requiring steroid treatment such as vasculitis, lupus,
             rheumatoid arthritis

          -  B-type natriuretic peptide (BNP) >400 pg/mL

          -  Pregnant or lactating

          -  Currently taking a beta blocker, a CYP2C8 inhibitor or inducer such as gemfibrozil or
             rifampin, a TZD (thiazolidinedione), or allergic to TZD

          -  Taking antioxidants or nutritional supplements (stable dose of calcium, vitamin D, or
             multivitamin is OK)

          -  Illicit drug use within the past year

          -  Current/active upper respiratory infection (if active URI, wait until asymptomatic for
             1 week to enroll)

          -  Asthma exacerbation within the past 4 weeks (includes ER, urgent care, or hospital
             visits due to asthma resulting in an increase in asthma-related medications)

          -  Undergoing evaluation for sleep apnea, or plans to institute treatment for sleep apnea
             (patients on a stable treatment regimen for sleep apnea for the last 3 months will be
             allowed to participate)

          -  Clinically significant abnormalities present on screening 12-lead electrocardiogram

          -  Women of childbearing potential using oral contraceptives who are not willing to use a
             second method of contraception during the study
Clinical trial NCT01397422 (phase 2/phase 3, status: completed)
Conditions: dyskinesia, levodopa induced dyskinesia, parkinson's disease
ICD codes: K22.4, G24.01, K22.4, G24.01, G20
Drugs: ads-5102 (extended release amantadine hcl)
SMILES: NC12CC3CC(CC(C3)C1)C2
Eligibility criteria:

        Inclusion Criteria:

          -  Signed a current IRB/IEC-approved informed consent form

          -  Parkinson's disease, per UK Parkinson's Disease Society (UKPDS) Brain Bank Clinical
             Diagnostic Criteria

          -  On a stable regimen of antiparkinson's medications , including any levodopa
             preparation administered not less than three times daily, and willing to continue the
             same doses and regimens during study participation

          -  Experiencing troublesome dyskinesia following levodopa dosing (peak dose dyskinesia)

          -  Able to understand and complete a standardized PD home diary, following training

        Exclusion Criteria:

          -  History of neurosurgical intervention related to Parkinson's disease (e.g. deep brain
             stimulation)

          -  History of seizures or stroke/TIA within 2 years of screening

          -  History of cancer within 5 years of screening, except adequately treated
             non-melanomatous skin cancers, localized bladder cancer, non-metastatic prostate
             cancer or in situ cervical cancer

          -  Estimated GFR < 50 mL/min/1.73m2

          -  Presence of cognitive impairment, as evidenced by a Mini-Mental Status Examination
             (MMSE) score of less than 24 during screening

          -  If female, is pregnant or lactating, or has a positive pregnancy test result pre-dose

          -  If a sexually active female, is not surgically sterile or at least 2 years
             post-menopausal, or does not agree to utilize an effective method of contraception
             from screening through at least 4 weeks after the completion of study treatment

          -  Treatment with an investigational drug or device within 30 days prior to screening

          -  Treatment with an investigational biologic within 6 months prior to screening
Clinical trial NCT00151047 (phase 2, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: capecitabine, docetaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Patients must have newly diagnosed prostate cancer with at least one of the following
        criteria:

          -  Clinical Stage > T2

          -  PSA > 15 ng/ml

          -  Biopsy Gleason's sum > 8

          -  All patients must have a minimum PSA value of > 5 ng/ml.

          -  Patients may not have evidence of distant systemic metastasis.

          -  Patients may not undergo concurrent hormonal, biologic, or chemotherapy.

          -  Patients may not have prior unanticipated severe reaction to fluoropyrimidine therapy
             or known hypersensitivity to 5-fluorouracil.

          -  Patients with a history of severe reaction to docetaxel or other drugs formulated with
             polysorbate 80 will not be eligible.

          -  Patients may not have an underlying cardiac disease.
Clinical trial NCT00501111 (phase 2, status: completed)
Conditions: alzheimer disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: azd3480, donepezil
SMILES: O=S(=O)(C1=CC=CC=C1)C1=CN=C2C(C=CC=C2N2CCNCC2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Provision of informed consent from patient and caregiver

          -  Clinical prognosis of probable Alzheimer's disease

          -  Patient must have a caregiver visiting the patient at least three times weekly

        Exclusion Criteria:

          -  Significant neurologic disease or dementia other than Alzheimer's disease

          -  Major depressive disorder, other major psychiatric disorder

          -  Use of acetylcholinesterase inhibitor or memantine for treatment of Alzheimer's
             disease within 8 weeks prior to enrollment

          -  Impaired vision and/or hearing making cognitive testing difficult
Clinical trial NCT00264004 (phase 2, status: completed)
Conditions: tumors
ICD codes: E88.3, R97.8, C49.A0, C49.A1, C49.A2, C49.A5, C49.A3
Drugs: azd2171
SMILES: COC1=CC2=C(C=C1OCCCN1CCCC1)N=CN=C2OC1=C(F)C2=C(NC(C)=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histological or cytological confirmation of advanced solid tumour, which is refractory
             to standard therapies or for which no standard therapy exists and for which there is a
             rationale for the therapeutic use of a vascular endothelial growth factor receptor
             (VEGFR) tyrosine kinase inhibitor.

        Exclusion Criteria:

          -  Prior treatment with a VEGF inhibitor

          -  Poorly controlled hypertension
Clinical trial NCT00402337 (phase 2, status: completed)
Conditions: chronic constipation
ICD codes: K59.04
Drugs: linaclotide acetate, matching placebo
SMILES: [H][C@]1(CSSC[C@]2([H])NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]3CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CSSC[C@H](N)C(=O)N3)NC2=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)NCC(=O)N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Patient is 18 years of age or older

          -  Patient meets colonoscopy requirements according to the American Gastroenterological
             Association

          -  Patient meets criteria for chronic constipation including weekly bowel movement
             frequency requirements and reports one or more symptoms of constipation according to
             protocol requirements

          -  Patient has successfully completed study requirements with no clinically-significant
             findings: physical exam, ECG, clinical laboratory tests

          -  Patient is fluent in English

        Exclusion Criteria:

          -  Patient reports loose or watery stools

          -  Patient meets criteria for IBS including protocol-defined abdominal discomfort or pain

          -  Patient may not take prohibited medications per protocol

          -  Medical diagnoses, medical conditions, or family history that would not make the
             patient a good candidate for the study or limit the patient's ability to complete the
             clinical study
Clinical trial NCT01361802 (phase 2, status: completed)
Conditions: pharyngitis, pain
ICD codes: A54.5, J02.0, J31.2, B08.5, J02.9, A50.03, J02.8, N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: ambroxol spray, ambroxol spray, ambroxol spray, placebo spray
SMILES: NC1=C(Br)C=C(Br)C=C1CN[C@H]1CC[C@H](O)CC1, NC1=C(Br)C=C(Br)C=C1CN[C@H]1CC[C@H](O)CC1, NC1=C(Br)C=C(Br)C=C1CN[C@H]1CC[C@H](O)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          1. Sore throat due to acute pharyngitis (not more than 72 hours);

          2. Score of 6 or greater on an 11-point pain intensity numerical rating scale;

          3. Willingness to remain at the study centre for one hour following the first dose of
             study medication and return one to three days later.

          4. Willing to take nothing by mouth except study medication for three hours following the
             first intake of study medication. Patients must also not smoke during this time
             period.

        Exclusion criteria:

          1. Known allergy to and/or hypersensitivity to ambroxol, sorbitol, or Acetaminophen;

          2. Patients with drug dependence and/or alcohol abuse;

          3. Use of any throat lozenge, throat spray, cough drop, menthol-containing product, or
             any product with demulcent properties within last 2 hours;

          4. Use of any analgesic/anti-pyretic within last 4 hours;

          5. Use of any "cold medication" (e.g. decongestant, antihistamine, expectorant,
             anti-tussive) within last eight hours;

          6. Use of an antibiotic for an acute illness within last 24 hours;

          7. Use of inhaled steroids or beta-agonists on a continuous basis during the last week;

          8. Use of any investigational therapy (including a marketed drug taken for an
             investigational indication) within last 30 days

          9. Any sign of mouth-breathing due to nasal congestion;

         10. Cough that causes throat discomfort;

         11. Active pulmonary disease such as bronchopneumonia;

         12. Pregnant, lactating or breastfeeding women,

         13. Any medical or psychiatric condition which, in the opinion of the investigator, could
             increase the risks associated with participation in an investigational study or affect
             compliance with the protocol.

         14. Patients who have previously enrolled in this study